The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks over ...

Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...

Stanley Goldfarb, Do No Harm's chair, in a statement said it was pleased the court "reversed course and correctly recognized our right to protect our members in the district court." Pfizer in a ...

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Pfizer targets $4 billion in operational savings ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...

Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market cap in early trading on Tuesday after Pfizer (NYSE ... compared to no ratings over the first six months of the year.

Here are three reasons to consider buying Pfizer like there's no tomorrow -- today. As terrible as COVID-19 was for society, it was undeniably a windfall for Pfizer. The company's two COVID-19 ...

Here are three reasons to consider buying Pfizer like there's no tomorrow -- today. 1. The business is trending up again As terrible as COVID-19 was for society, it was undeniably a windfall for ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.